MATN Mateon Therapeutics Inc.

MATEON TO PARTICIPATE IN MERIDIAN CLINICAL TRIALS SUMMIT

MATEON TO PARTICIPATE IN MERIDIAN CLINICAL TRIALS SUMMIT
EN
14/10/2020

Underlying

MATNMateon Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Mateon Therapeutics Inc.

 PRESS RELEASE
Free
MATN Mateon Therapeu...

Sapu Nano to present at the 2025 San Antonio Breast Cancer Symposium (...

Sapu Nano to present at the 2025 San Antonio Breast Cancer Symposium (SABCS) Highlighting Sapu003 (Deciparticle™ Everolimus) AGOURA HILLS, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat cancer patients by leveraging its novel PDAOAI platform and deep knowledge in nanomedicines and the tumor microenvironment, announced today that Sapu Nano will be featuring its investigational intravenous Deciparticle™ everolimus (Sapu003) have been accepted fo...

October 30, 2025 1 EN
 PRESS RELEASE
Free
MATN Mateon Therapeu...

Oncotelic to present at the 2025 San Antonio Breast Cancer Symposium (...

Oncotelic to present at the 2025 San Antonio Breast Cancer Symposium (SABCS) Highlighting Sapu003 (Deciparticle™ Everolimus) Accepted Presentations Showcase First-in-Human Development, Manufacturing Innovation, and Predictive Biomarkers for Deciparticle™ Everolimus (Sapu003) AGOURA HILLS, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat cancer patients by leveraging its novel PDAOAI platform and deep knowledge in nanomedicines and the tumor mic...

October 23, 2025 1 EN
 PRESS RELEASE
Free
MATN Mateon Therapeu...

Oncotelic to Present at the LD Micro Main Event XIX

Oncotelic to Present at the LD Micro Main Event XIX AGOURA HILLS, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat cancer patients by leveraging its novel PDAOAI platform and deep knowledge in nanomedicines and the tumor microenvironment, announced today that it will be presenting at the 19th Annual Main Event on Tuesday, October 21, at 11:30 a.m. PT at the Hotel del Coronado in San Diego, California. Vuong Trieu, Ph.D., CEO, will be giving the ...

October 20, 2025 1 EN
 PRESS RELEASE
Free
MATN Mateon Therapeu...

Oncotelic Therapeutics Showcases Robust Pipeline and Founder’s Broad I...

Oncotelic Therapeutics Showcases Robust Pipeline and Founder’s Broad Intellectual Property Contributions to Biopharma Industry Highlighting multibillion-dollar drug discoveries and advancing novel oncology and immunotherapy assets AGOURA HILLS, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (“OTLC” or the “Company”), a clinical stage biopharmaceutical company developing transformative oncology and immunotherapy treatments, today highlights the depth of its oncology and immunotherapy pipeline while recognizing the extraordinary intellectual property c...

August 28, 2025 1 EN
 PRESS RELEASE
Free
MATN Mateon Therapeu...

Oncotelic Therapeutics Highlights Peer‑Reviewed Publication Linking TG...

Oncotelic Therapeutics Highlights Peer‑Reviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer Patients Data support further evaluation of investigational antisense OT‑101 (trabedersen) as a TGFB2‑targeted approach in pancreatic ductal adenocarcinoma (PDAC). AGOURA HILLS, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (“Oncotelic” or the “Company”), a clinical‑stage biopharmaceutical company developing RNA‑targeted and small‑molecule therapeutics for cancer and rare diseases, today highlighted the publication of new translational ...

July 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch